Spatial patterns of brain amyloid-β burden and atrophy rate associations in mild cognitive impairment

Brain

Volumn 134, Issue 4, 2011, Pages 1077-1088

  Tosun, Duygu ^a   Schuff, Norbert ^a,b   Mathis, Chester A ^c   Jagust, William ^d   Weiner, Michael W ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

11C PiB PET; Alzheimer's disease; amyloid; amyloid ; brain atrophy rate; mild cognitive impairment; MRI; multimodal brain imaging

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CEREBELLUM; CUNEUS; DISEASE ASSOCIATION; FEMALE; HUMAN; INFERIOR PARIETAL LOBULE; MAJOR CLINICAL STUDY; MALE; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 79953647082     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr044     Document Type: Article

References (96)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-17.
2. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and A[beta]42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8. (Pubitemid 29415689)
3. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain 2006; 129: 2867-73. (Pubitemid 44684509)
4. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-7.
5. Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC. Does Alzheimer's disease affect hippocampal asymmetry? evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord 2005; 19: 338-44. (Pubitemid 40663329)
6. Becker JT, Davis SW, Hayashi KM, Meltzer CC, Toga AW, Lopez OL, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol 2006; 63: 97-101. (Pubitemid 43063867)
7. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B Methodol 1995; 57: 289-300.
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13. (Pubitemid 37162569)
9. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, et al. b-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-7.
10. Bouwman FH, Schoonenboom SNM, van der Flier WM, van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007; 28: 1070-4. (Pubitemid 46635910)
11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
12. Cabeza R, Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci 2000; 12: 1-47. (Pubitemid 30142782)
13. Calhoun VD, Adali T. Feature-based fusion of medical imaging data. IEEE Trans Inf Technol Biomed 2009; 13: 711-20.
14. Calhoun VD, Adali T, Pearlson GD, Pekar JJ. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp 2001; 14: 140-51. (Pubitemid 33032347)
15. Chetelat Ga, Baron J-C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. NeuroImage 2003; 18: 525-41. (Pubitemid 36269160)
16. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-24.
17. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-4 levels in vivo. Neuron 2005; 48: 913-22. (Pubitemid 41814696)
18. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and b-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-702. (Pubitemid 37521622)
19. Colliot O, Ché telat G, Chupin M, Desgranges B, Magnin B, Benali H, et al. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology 2008; 248: 194-201.
20. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007; 64: 108-15. (Pubitemid 46072432)
21. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 949-56.
22. Desikan RS, Fischl B, Cabral HJ, Kemper TL, Guttmann CRG, Blacker D, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal Alzheimer's disease. Neurology 2008; 71: 819-25.
23. deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al, MRI-derived entorhinal volume is a good predictor of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging, 2004, 25, 1197-203. (Pubitemid 39094022)
24. Devanand DP, Mikhno A, Pelton GH, Cuasay K, Pradhaban G, Dileep Kumar JS, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxy-glucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010; 23: 185-98.
25. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nonde-mented elderly. Ann Neurol 2006; 60: 688-95. (Pubitemid 46048486)
26. Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, Kraut MA, et al. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging 2010: doi:10.1016/ j.neurobiolaging.2009.12. 008.
27. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol, Neurosurg Psychiatry 2001; 71: 441-7. (Pubitemid 32906865)
28. Du AT, Schuff N, Kramer JH, Ganzer S, Zhu XP, Jagust WJ, et al. Higher atrophy rate of entorhinal cortex than hippocampus in Alzheimer's disease. Neurology 2004; 62: 422-7. (Pubitemid 38200854)
29. Du AT, Schuff N, Zhu XP, Jagust WJ, Miller BL, Reed BR, et al. Atrophy rates of entorhinal cortex in Alzheimer's disease and normal aging. Neurology 2003; 60: 481-6. (Pubitemid 36188246)
30. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8.
31. Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in mild cognitive impairment patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. NeuroImage 2008; 39: 1731-43. (Pubitemid 351179414)
32. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease. J Neurosci 2010; 30: 2088-101.
33. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
34. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeco-nomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008; 65: 113-20.
35. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009; 72: 1504-11.
36. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
37. Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clin-icopathologic study. Arch Neurol 2005; 62: 758-65. (Pubitemid 40656091)
38. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004; 101: 4637-42. (Pubitemid 38437463)
39. Hagler DJ Jr, Saygin AP, Sereno MI. Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. NeuroImage 2006; 33: 1093-103. (Pubitemid 44708789)
40. Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, et al. Correlation of cerebrospinal fluid levels of tauprotein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-3. (Pubitemid 40656092)
41. Hedden T, Van Dijk KRA, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29: 12686-94.
42. Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, et al. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. NeuroImage 2008; 41: 19-34.
43. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in Alzheimer's disease. Neurology 2004; 62: 591-600. (Pubitemid 38252801)
44. Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic mild cognitive impairment. Neurology 2005; 65: 1227-31. (Pubitemid 41508215)
45. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008a; 27: 685-91. (Pubitemid 351508080)
46. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008b; 131: 665-80. (Pubitemid 351294719)
47. Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008c; 70: 1740-52. (Pubitemid 351653966)
48. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-65.
49. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-28.
50. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-9.
51. Joshi S, Davis B, Jomier M, Gerig G. Unbiased diffeomorphic atlas construction for computational anatomy. NeuroImage 2004; 23 (Suppl 1): S151-60. (Pubitemid 39421714)
52. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 2003; 37: 925-37. (Pubitemid 36398299)
53. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80. (Pubitemid 44747926)
54. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-6. (Pubitemid 46717985)
55. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19. (Pubitemid 38269583)
56. Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp 2009; 30: 241-55.
57. Lockhart A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 2006; 11: 1093-9. (Pubitemid 44803111)
58. Lopez OL, Kuller LH, Becker JT, Dulberg C, Sweet RA, Gach HM, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2007; 64: 416-20. (Pubitemid 46425698)
59. Lorenzen P, Davis B, Joshi S. Unbiased atlas formation via large deformations metric mapping. Med Image Comput Comput Assist Interv 2005; 8 (Pt 2): 411-8. (Pubitemid 43828391)
60. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007; 34: 809-22. (Pubitemid 47503823)
61. McGee KP, Grimm RC, Felmlee JP, Rydberg JR, Riederer SJ, Ehman RL. The shoulder: adaptive motion correction of MR images. Radiology 1997; 205: 541-5. (Pubitemid 27467339)
62. Mikhno A, Devanand D, Pelton G, Cuasay K, Gunn R, Upton N, et al. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. J Nucl Med 2008; 49: 1262-9.
63. Mintun M. Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer's disease. CNS Spectr 2005; 10 (11 Suppl 18): 13-6. (Pubitemid 41784922)
64. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52. (Pubitemid 44214969)
65. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated b-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-23.
66. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. NeuroImage 2008; 43: 59-68.
67. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp 2009a; 30: 2766-88.
68. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. NeuroImage 2009b; 45 (1 Suppl): S3-15.
69. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4. (Pubitemid 23346995)
70. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound b imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-75.
71. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 2007; 20: 398-402. (Pubitemid 47051985)
72. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 2008; 35 (Suppl 1): S46-50.
73. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435-40.
74. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201-9.
75. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66: 1447-55.
76. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. b-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-44. (Pubitemid 350033975)
77. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47. (Pubitemid 41541962)
78. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging b-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25. (Pubitemid 46763260)
79. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. NeuroImage 2009; 47: 1196-206.
80. Shattuck DW, Leahy RM. BrainSuite: an automated cortical surface identification tool. Med Image Anal 2002; 6: 129-42. (Pubitemid 35282822)
81. Sperling RA, LaViolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-88.
82. Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005; 64: 1520-4. (Pubitemid 40617686)
83. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of grey matter loss in Alzheimer's disease. J Neurosci 2003; 23: 994-1005. (Pubitemid 36206191)
84. Thompson PM, Hayashi KM, de Zubicaray GI, Janke AL, Rose SE, Semple J, et al. Mapping hippocampal and ventricular change in Alzheimer disease. NeuroImage 2004; 22: 1754-66. (Pubitemid 38962663)
85. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009a; 50: 1464-70.
86. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009b; 50: 191-7.
87. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 2010; 31: 1340-54.
88. Villemagne V, Fodero-Tavoletti M, Pike K, Cappai R, Masters C, Rowe C. The ART of loss: Ab Imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol 2008; 38: 1-15.
89. Wechsler D. Wechsler Memory Scale-Revised (WMS-R). New York: Psychological Corporation; 1987.
90. Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007; 130: 1777-86. (Pubitemid 47343806)
91. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to Alzheimer's disease in amnestic mild cognitive impairment. Neurology 2008; 70: 512-20. (Pubitemid 351653375)
92. Wilson AA, Garcia A, Chestakova A, Kung H, Houle S. A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-11C 2-(4prime-methylaminophenyl)-6-hydroxybenzothiazole (11C-6-OH-BTA-1). J Labelled Comp Radiopharm 2004; 47: 679-82. (Pubitemid 39390042)
93. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comp Assist Tomogr 1993; 17: 536-46. (Pubitemid 23206731)
94. Worsley KJ, Taylor JE, Tomaiuolo F, Lerch J. Unified univariate and multi-variate random field theory. NeuroImage 2004; 23 (Suppl 1): S189-95. (Pubitemid 39421718)
95. Yvette IS, Marcus ER, Abraham ZS, John CM, Denise H, Suzhi W, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010; 67: 584-7.
96. Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 2010; 133: 1352-67.